Type of Hodgkin's lymphoma-Classical Hodgkin's lymphma Posts on Medivizor
Navigation Menu

Type of Hodgkin’s lymphoma-Classical Hodgkin’s lymphma Posts on Medivizor

Evaluating the use of high-dose chemotherapy for the treatment of patients with high-risk relapsed Hodgkin lymphoma.

Evaluating the use of high-dose chemotherapy for the treatment of patients with high-risk relapsed Hodgkin lymphoma.

Posted by on Jun 13, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) for the treatment of patients with high-risk relapse (HRR) classical Hodgkin’s lymphoma (cHL). The authors concluded that the outcomes of patients with HRR cHL have improved over the last 15 years with...

Read More

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Posted by on Jun 6, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether brentuximab vedotin (Adcedris; BC) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combination resulted in a reduction or elimination of consolidative radiotherapy in early-stage unfavorable-risk Hodgkin lymphoma (HL). The data showed that the BV+AVD combination with and without...

Read More

Evaluating the safety and effectiveness of brentuximab vedotin for children with high-risk Hodgkin lymphoma.

Evaluating the safety and effectiveness of brentuximab vedotin for children with high-risk Hodgkin lymphoma.

Posted by on May 23, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of incorporating brentuximab vedotin (BV; Adcetris) as a substitution for vincristine in the OEPA (vincristine, etoposide, prednisone, doxorubicin) or COPD (cyclophosphamide, vincristine, prednisone, dacarbazine) chemotherapy regimen in children with high-risk classical...

Read More

Is autologous stem cell transplantation after anti-PD-1 therapy an effective treatment for patients with relapsed or refractory Hodgkin lymphoma?

Is autologous stem cell transplantation after anti-PD-1 therapy an effective treatment for patients with relapsed or refractory Hodgkin lymphoma?

Posted by on May 15, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors assessed the effectiveness of autologous stem cell transplantation (ASCT) after anti-PD-1 therapy for the treatment of patients with high-risk relapsed/refractory (r/r) Hodgkin lymphoma (HL). The study found that ASCT after anti-PD-1 therapy had very good outcomes in patients with r/r HL. Some background Standard...

Read More

Evaluating the effectiveness of BGD therapy in relapsed/refractory Hodgkin lymphoma

Evaluating the effectiveness of BGD therapy in relapsed/refractory Hodgkin lymphoma

Posted by on Mar 28, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of the BGD (bendamustine, gemcitabine, and dexamethasone) regimen in patients with previously treated Hodgkin lymphoma (HL). This study concluded that BGD is well-tolerated and highly effective in these patients.  Some background Hodgkin lymphoma (HL) is a cancer that...

Read More

Relapsed or refractory Hodgkin lymphoma: how does stopping and restarting nivolumab impact patient outcomes?

Relapsed or refractory Hodgkin lymphoma: how does stopping and restarting nivolumab impact patient outcomes?

Posted by on Mar 28, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate the safety and effectiveness of stopping and restarting nivolumab (Opdivo) in patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).   The authors concluded that nivolumab retreatment is well tolerated and effective in patients who achieved complete response (CR; complete...

Read More

Pembrolizumab followed by AVD treatment in newly diagnosed advanced classical Hodgkin lymphoma

Pembrolizumab followed by AVD treatment in newly diagnosed advanced classical Hodgkin lymphoma

Posted by on Oct 25, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of pembrolizumab (Keytruda) followed by AVD (doxorubicin, vinblastine, and dacarbazine) treatment in patients with high-risk classical Hodgkin lymphoma.  This study concluded that this treatment was safe and effective in these patients.   Some...

Read More

The impact of G-CSF on brentuximab vedotin plus chemotherapy in treating newly diagnosed advanced Hodgkin lymphoma

The impact of G-CSF on brentuximab vedotin plus chemotherapy in treating newly diagnosed advanced Hodgkin lymphoma

Posted by on Sep 20, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated the impact of granulocyte-colony stimulating factor (G-CSF; Neupogen) on the outcomes of brentuximab-vedotin (BV; Adcetris) plus chemotherapy in newly diagnosed patients with stage-III/IV Hodgkin lymphoma (HL). The authors found that G-CSF improved the safety and efficacy outcomes of the combination therapy in such...

Read More

Do survivors of childhood Hodgkin lymphoma have a risk of lung damage?

Do survivors of childhood Hodgkin lymphoma have a risk of lung damage?

Posted by on Aug 30, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the lung function of patients with classical Hodgkin lymphoma (HL) in the first years of remission. It found that these survivors had higher rates of lung damage. Some background HL is a cancer of the lymph nodes which most often affects children and young adults. HL has good outcomes, and most patients with HL will...

Read More

Allogeneic stem cell transplant in patients with classic Hodgkin lymphoma who have been treated with immune checkpoint inhibitors

Allogeneic stem cell transplant in patients with classic Hodgkin lymphoma who have been treated with immune checkpoint inhibitors

Posted by on Aug 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of allogeneic stem cell transplantation (alloSCT) after immune checkpoint inhibitor (ICI) treatment in patients with classic Hodgkin lymphoma (cHL).   This study concluded that this treatment is safe and has very good outcomes in these...

Read More

Evaluating long-term pembrolizumab for relapsed Hodgkin lymphoma

Evaluating long-term pembrolizumab for relapsed Hodgkin lymphoma

Posted by on Jul 26, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the effect of pembrolizumab (Keytruda) to treat classical Hodgkin lymphoma (cHL) which had relapsed after previous treatments including brentuximab vedotin (Adcetris). It found that pembrolizumab was effective for these patients. Some background cHL is typically treated with chemotherapy, and sometimes with radiation...

Read More